CryoPort (NASDAQ:CYRX) Stock Price Crosses Above 200-Day Moving Average - What's Next?

Key Points

• CryoPort, Inc. shares have surpassed their 200-day moving average, trading at $9.94, with a peak of $10.27, indicating positive momentum in the stock.
• Analysts have shown varied opinions on CryoPort, with upgrades from Leerink Partners and BTIG Research, resulting in a target price range up to $16.00, while Weiss Ratings maintains a sell rating.
• The company reported disappointing quarterly earnings, with a loss of ($0.29) EPS, underperforming against the consensus estimate of ($0.20), despite revenue exceeding expectations at $45.45 million.

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $7.36 and traded as high as $10.27. CryoPort shares last traded at $9.94, with a volume of 370,779 shares changing hands.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Leerink Partnrs upgraded shares of CryoPort from a "hold" rating to a "strong-buy" rating in a report on Wednesday, August 6th. Weiss Ratings restated a "sell (d+)" rating on shares of CryoPort in a report on Wednesday. Leerink Partners upgraded CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 target price for the company in a report on Wednesday, August 6th. BTIG Research lifted their price objective on shares of CryoPort from $10.00 to $15.00 and gave the company a "buy" rating in a report on Thursday, September 18th. Finally, Stephens initiated coverage on shares of CryoPort in a research note on Tuesday, July 22nd. They set an "overweight" rating and a $13.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $12.56.

CryoPort Stock Down 1.2%

The firm has a 50 day moving average price of $9.03 and a 200-day moving average price of $7.36. The company has a current ratio of 16.24, a quick ratio of 15.47 and a debt-to-equity ratio of 0.39. The firm has a market cap of $497.70 million, a PE ratio of 7.47 and a beta of 1.61.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.09). The company had revenue of $45.45 million during the quarter, compared to analysts' expectations of $41.74 million. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort has set its FY 2025 guidance at EPS. Research analysts forecast that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

Insider Activity

In other news, Director Robert J. Hariri sold 25,000 shares of the stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $9.71, for a total value of $242,750.00. Following the transaction, the director owned 51,275 shares in the company, valued at approximately $497,880.25. This represents a 32.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Robert Stefanovich sold 9,300 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $8.67, for a total value of $80,631.00. Following the sale, the chief financial officer owned 207,213 shares of the company's stock, valued at approximately $1,796,536.71. The trade was a 4.30% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 80,028 shares of company stock worth $661,252. 10.00% of the stock is currently owned by company insiders.

Institutional Trading of CryoPort

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CYRX. Nisa Investment Advisors LLC raised its holdings in CryoPort by 299.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company's stock worth $27,000 after purchasing an additional 2,729 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock worth $44,000 after purchasing an additional 4,375 shares in the last quarter. SBI Securities Co. Ltd. raised its holdings in CryoPort by 548,750.0% during the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock worth $67,000 after purchasing an additional 10,975 shares in the last quarter. CWM LLC raised its holdings in CryoPort by 1,437.0% during the first quarter. CWM LLC now owns 11,328 shares of the company's stock worth $69,000 after purchasing an additional 10,591 shares in the last quarter. Finally, ProShare Advisors LLC acquired a new stake in CryoPort during the second quarter worth approximately $75,000. Institutional investors and hedge funds own 92.90% of the company's stock.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.